James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Some Retailers Are Thriving in the ‘Showrooming Era’

Dick's and other sporting goods firms are proving durable against the "look in-store, buy online" trend. Here's why.

One Home Improvement Industry Doesn’t Need a Strong Housing Market

While home-improvement retailers like Lowe's and Home Depot can be vulnerable to weaker housing markets, paint stocks are more durable.

Cheap Chinese Solar Panels Actually AREN’T the Problem

While solar-stock investors watch the EU-China "dumping" accusations on pins and needles, that nuance is obscuring a much more important detail.

4 Dow Stocks to Dump Right Now

Here is a look at four Dow names that you not only shouldn't buy right now, but that some investors should consider selling in light of their growing risk.

Believe In This M&A Mastermind

Including its Medicis deal, Valeant Pharmaceuticals has made 27 acquisitions in the past four-plus years -- and it's showing no signs of capsizing.